Proportion with adverse events · patients with AD and epileptic seizures
It is very uncertain whether levetiracetam changes proportion with adverse events compared with phenobarbital (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: Deterioration of symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ any adverse effect · patients with antipsychotic‐induced tardive dyskinesia
ANTIEPILEPTIC ‐ LEVETIRACETAM showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Recurrent seizure at 12 months · children with febrile seizures
It is very uncertain whether intermittent oral levetiracetam changes recurrent seizures at 12 months compared with placebo (any antipyretics) (very low certainty).
1 finding from 1 review
Recurrent seizure at 18 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 24 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 36 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 48 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 60 months or greater · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 6 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 3: anticonvulsant levetiracetam changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
Comparison 3: anticonvulsant levetiracetam showed no clear difference in global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of infants who achieve seizure control after the first loading dose of ASM · neonates with EEG‐confirmed seizures
Summary of findings table ‐ Phenobarbital probably leads to higher proportion of infants who achieve seizure control after the first… compared with levetiracetam (moderate certainty).
1 finding from 1 review
Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with clinically diagnosed seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found